findmyKOL

Steven Gubin, MD

Basic profile

The Stern Cardiovascular Foundation

ORCIDNone on fileNPI
RegionMemphis, TN · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Steven Gubin is a Cardiology physician affiliated with The Stern Cardiovascular Foundation. OpenAlex indexes 17 publications with 302 citations (h-index 4).

Overview

Scholarship

indexed output and impact (OpenAlex)
17publications

Distinct works indexed by OpenAlex.

302citations

Total citations across indexed works.

4h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
15companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

15 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    91.4%
    Other lipid modifying agents44.7%
    Inclisiran100%Vascepa1%
    Part D + Part B23 patients
    Statin11.5%
    Rosuvastatin Calcium59%Atorvastatin Calcium34%Pravastatin Sodium3%Simvastatin3%Livalo1%
    Part D<11 patients

    + 25 more classes in this area

  • Blood & clotting

    5.7%
    Factor Xa inhibitor4.4%
    Eliquis74%Xarelto26%
    Part D212 patients
    P2Y12 inhibitor0.9%
    Clopidogrel89%Brilinta11%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    2.5%
    SGLT2 inhibitor1%
    Jardiance58%Farxiga42%
    Part D36 patients
    Potassium supplement0.8%
    Potassium Chloride89%Klor-Con M2012%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)5.8% facility · 94.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”